Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Change in Receivables (2023 - 2025)

Historic Change in Receivables for Phathom Pharmaceuticals (PHAT) over the last 3 years, with Q3 2025 value amounting to $4.5 million.

  • Phathom Pharmaceuticals' Change in Receivables fell 5543.98% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.7 million, marking a year-over-year increase of 6500.57%. This contributed to the annual value of $37.2 million for FY2024, which is 217000.61% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Change in Receivables stood at $4.5 million for Q3 2025, which was down 5543.98% from $14.9 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Change in Receivables high stood at $17.7 million for Q4 2024, and its period low was -$2.4 million during Q1 2025.
  • In the last 3 years, Phathom Pharmaceuticals' Change in Receivables had a median value of $5.8 million in 2024 and averaged $7.0 million.
  • Per our database at Business Quant, Phathom Pharmaceuticals' Change in Receivables surged by 98399.51% in 2024 and then tumbled by 20847.08% in 2025.
  • Over the past 3 years, Phathom Pharmaceuticals' Change in Receivables (Quarter) stood at $1.6 million in 2023, then skyrocketed by 984.0% to $17.7 million in 2024, then plummeted by 74.45% to $4.5 million in 2025.
  • Its last three reported values are $4.5 million in Q3 2025, $14.9 million for Q2 2025, and -$2.4 million during Q1 2025.